Skip to content

A verification study of the suppressive effect on the elevation of blood glucose level: a randomized, placebo-controlled, open-label, crossover comparison study

A verification study of the suppressive effect on the elevation of blood glucose level: a randomized, placebo-controlled, open-label, crossover comparison study - A verification study of the suppressive effect on the elevation of blood glucose level

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000053899
Enrollment
10
Registered
2024-03-19
Start date
2024-03-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese

Interventions

Duration: Once Test food: &lt
Tea beverage &lt
Placebo beverage *The intervention sequence is Test 1 to Test 2. *Washout period is for one week and more. Duration: Once Test food: &lt
Placebo beverage &lt
Tea beverage *The intervention sequence is Test 1 to Test 2. *Washout period is for one week and more.

Sponsors

ORTHOMEDICO Inc.
Lead Sponsor
Medical Corporation Seishinkai, Takara Clinic Nerima Medical Association, Minami-machi Clinic
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Japanese 2. Men or women 3. Individuals aged between 20 and 64 4. Healthy individuals 5. Individuals whose fasting blood glucose level is >=70 and <126 mg/dL, whose blood glucose level at 120 minutes after consumption of a carbohydrate load (Trelan-G 75 g) is <200 mg/dL, and whose Cmax of the glucose after consumption of a carbohydrate load (Trelan-G 75 g) is <=140 mg/dL at screening (before consumption; Scr)

Exclusion criteria

Exclusion criteria: 1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims" 5. Individuals who are taking or using medications (including herbal medicines) and supplements 6. Individuals who are allergic to medicines and/or foods related to the test product, particularly who show allergic reactions to green tea, rice, and/or agar 7. Individuals who are pregnant, lactating, or planning to become pregnant during this study 8. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate another study during this study 9. Individuals who are judged as ineligible to participate in this study by the physician

Design outcomes

Primary

MeasureTime frame
1. The maximum blood concentration (Cmax) of the glucose 2. The incremental area under the curve (IAUC) of the blood glucose

Secondary

MeasureTime frame
1. The total AUC (TAUC), delta Cmax (difference from before carbohydrate load to Cmax), and the time to maximum blood concentration (Tmax) of the blood glucose 2. IAUC and Cmax of the blood insulin levels 3. The measured values of the blood glucose and insulin levels at 0, 30, 60, 90, and 120 minutes after consumption of the carbohydrate load, and the amount of changes of each item from 0 minutes after consumption of the carbohydrate load

Countries

Japan

Contacts

Public ContactNaoko Suzuki

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026